Arcus Biosciences, Inc. (RCUS)
| Market Cap | 2.35B |
| Revenue (ttm) | 77.52M |
| Net Income (ttm) | -122.86M |
| Shares Out | 64.92M |
| EPS (ttm) | -2.24 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 19 |
| Last Price | $32.23 |
| Previous Close | $33.13 |
| Change ($) | -0.90 |
| Change (%) | -2.72% |
| Day's Open | 32.68 |
| Day's Range | 32.16 - 33.35 |
| Day's Volume | 73,338 |
| 52-Week Range | 16.69 - 42.36 |
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today presented progression-free su...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensati...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensati...
Arcus Biosciences, Inc. (RCUS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strengt...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensati...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensati...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today reported financial results fo...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management wil...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensati...
Arcus Biosciences Inc. disclosed Monday that Gilead Sciences Inc. boosted its stake in the oncology-focused biopharmaceutical company, through the purchase of $220.35 million worth of stock. Arcus share...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Gilead Science...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensati...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today presented preliminary data fr...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensati...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that preliminary da...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Andrew Perlman...
Investors need to pay close attention to Arcus Biosciences (RCUS) stock based on the movements in the options market lately.
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensati...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, and WuXi Biologics (2269.HK), a glo...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management wil...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensati...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced financial results f...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced a collaboration wit...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Jennifer Jarre...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc.
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc.
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc.
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc.
Arcus Biosciences, Inc. (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Arcus Biosciences, Inc.: An Oncology Stock With Newfound Prominence
FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS), an oncology-focused biopharmaceutical company working to create bes...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Bob Goeltz wil...
Is (RCUS) Outperforming Other Medical Stocks This Year?
Is (RCUS) Outperforming Other Medical Stocks This Year?
Arcus Biosciences (RCUS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
The development-stage biopharma is bouncing back from a recent stock dip.
Investors expecting a buyout offer were disappointed by the collaboration agreement Gilead Sciences offered.
The deal gives Gilead access to a new pipeline of potential cancer immunotherapies.
Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -12.50% and -12.50%, respectively, for the quarter ended March 2020.
Is (RCUS) Outperforming Other Medical Stocks This Year?
Arcus Biosciences, Inc. (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Shares of Arcus Biosciences Inc. RCUS, +88.44% soared 87% in trading on Thursday after people familiar with the matter told Bloomberg News that Gilead Sciences Inc.
The two companies are apparently discussing either an equity purchase or some other form of cooperation.
Arcus Biosciences stock rocketed to a record high Thursday on reports suggesting Gilead Sciences could be interested in acquiring a stake in the Alphabet-backed biotech company.
Does Arcus Biosciences, Inc. (RCUS) have what it takes to be a top stock pick for momentum investors?
Arcus Biosciences stock is on fire in response to a possible partnership deal with Gilead Sciences.
Arcus Biosciences (RCUS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well
Arcus Biosciences Anti-TIGIT Candidate Puts Company In The Shop Window
Top Ranked Momentum Stocks to Buy for March 13th
Efforts to contain COVID-19 are putting the entire biopharmaceutical industry in a jam.
About RCUS
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company is also developing Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combi... [Read more...]
| Industry Biotechnology | IPO Date Mar 15, 2018 |
| Stock Exchange NYSE | Ticker Symbol RCUS |
Financial Performance
In 2020, RCUS's revenue was $77.52 million, an increase of 416.78% compared to the previous year's $15.00 million. Losses were -$122.86 million, 45.0% more than in 2019.
Analyst Forecasts
According to 11 analysts, the average rating for RCUS stock is "Strong Buy." The 12-month stock price forecast is 53.20, which is an increase of 65.06% from the latest price.